Markets:

Overview

News

Currencies

International

Treasuries

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

4.530 +0.210 (+4.86%)

Official Closing Price Updated: 8:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Can-Fite Biopharma Ltd American Depositary Shares

< Previous 1 2 3 4 Next >

Recap: Can Fite Biofarma Q3 Earnings ↗

November 30, 2023

Via Benzinga

Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today? ↗

November 21, 2023

Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of

Via Benzinga

Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

October 24, 2023

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page

Via Benzinga

Recap: Can Fite Biofarma Q1 Earnings ↗

June 01, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 05, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 02, 2023

Via Benzinga

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial ↗

June 29, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 13, 2023

It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 11, 2023

Via Benzinga

Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know ↗

March 30, 2023

Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

February 14, 2023

During Tuesday, 40 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

February 10, 2023

During Friday, 48 stocks hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 25, 2023

On Wednesday, 22 companies hit new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 04, 2023

On Wednesday, 35 companies reached new 52-week lows.

Via Benzinga

Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer ↗

December 28, 2022

Via Benzinga

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

December 27, 2022

By Ernest Dela Aglanu, Benzinga

Via News Direct

Multiple Shots On Goal: Can-Fite's Late-Stage Clinical Pipeline Hits Positive Results ↗

December 13, 2022

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer.

Via Benzinga

Meet This BioPharma Company With Several Exciting Drugs In Advanced Clinical Trials ↗

November 09, 2022

Sign up for this week’s All Access giveaway here! Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma (NYSE: CANF), was a guest on Benzinga’s All Access on Nov 4, 2022.

Via Benzinga

This Company Is Racing Toward Providing Comfort And Safety To Millions Of Psoriasis Sufferers ↗

October 27, 2022

The competition between pharmaceutical company trials to help the 2% to 3% of the population suffering from chronic psoriasis is heating up.

Via Benzinga

Smoking Pot Makes You 55% Less Likely To Develop This Deadly Cancer ↗

August 03, 2022

Marijuana users have 55% fewer chances of developing, one of the most common malignancies worldwide - hepatocellular carcinoma (HCC), according to a study

Via Benzinga

Industry Analysts Seemingly Sing Praises For This Stock After Phase III Trial Results ↗

July 14, 2022

Psoriasis is a common chronic disease mediated by the immune system. It’s characterized by red, scaly patches that form on the skin. Psoriasis affects more than 3% of the U.S. adult population — over...

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session ↗

July 12, 2022

Gainers

Via Benzinga

The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death ↗

July 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Alibaba, Zoom Video And 76 Biggest Movers From Yesterday ↗

July 12, 2022

Gainers Kaspien Holdings Inc. (NASDAQ: KSPN) shares climbed 161.9% to close at $6.81 on Monday on heavy volume amid mention of the stock on social media.

Via Benzinga

Aspen Aerogels And 28 Stocks Moving Premarket ↗

June 30, 2022

Gainers

Via Benzinga

Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday ↗

July 01, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase...

Via Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data ↗

June 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Is NeuroSense Therapeutics Jumping By 45%? 64 Stocks Moving In Thursday's Mid-Day Session ↗

June 30, 2022

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 171.3% to $1.70 after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical...

Via Benzinga

This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday ↗

June 30, 2022

Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Can-Fite Biopharma Ltd American Depositary Shares (NY:CANF)

Headline News about Can-Fite Biopharma Ltd American Depositary Shares

Starting at $3.75/week.

Subscribe Today